Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
Earlier Data Showed Better Results For Roche Pairing
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
